1) Chinese and Indian drug makers are on the verge of selling cheaper copies of complex biotech drugs to treat diseases like cancer, diabetes, and arthritis that are currently only affordable in rich nations.
2) This could transform healthcare in much of the world but spark backlash from major pharmaceutical companies and rich countries seeking to protect drug patents.
3) Advocates argue these copycat drugs could increase access to life-saving treatments, while others argue ensuring drug company profits is needed to drive innovation.
Eighty percent of Americans believe the prices of prescription medications are unreasonable. PharmacyChecker president and co-founder, Gabriel Levitt, spoke at the New York Retirees Association of District Council 37 September 2018 meeting about the prescription drug price crisis in America and how international online pharmacies can help seniors today. With around 200-300 members in attendance, the members didn’t hold back in expressing shock at the numbers surrounding the current state of drug prices in the United States vs. the rest of the world. Commonly prescribed drugs, that many uninsured or under-insured Americans can’t afford are much less in Canada and other countries.
In this SlideShare, we'll provide an overview of the biggest vaccination campaign in history. Since governments around the world began vaccinating their populations in December 2020, there is a striking gap between higher-income countries with the rest of the world. To date (10th June 2021), more than 2.25 billion doses have been administered, yet low-income countries are still far behind, receiving only 0.3% of doses administered.
Changing times ask for solid relationships.
Times are changing. A renewed interest from big pharma in the rare disease landscape
has awakened due to large-scale patent expirations, competition from generics &
biosimilars, anemic pipelines, escalating clinical trial costs and a global health-care
reform. This means that the traditional blockbuster model has become less viable while
the revenue-generating potential of orphan drugs has shown to be huge with a greater
return on investment than non-orphan drugs. According to EvaluatePharma, the orphan
drugs sales will grow at an annual rate of 11% and constitute 19% of the total share of
prescription drugs by 2020, totalling 176 billion dollars.
The rare disease landscape is very complex due to the large amount of stakeholders
involved. Despite their different interests they have one goal in common: getting an
orphan drug approval that will help save or improve lives. But there are many challenges
on the road to orphan drug designation:
• Complex and changing national and regional regulations
• Clinical trial design and finding & keeping patients
• The lack of a central database designed specifically to list patient registries, which
asks for close stakeholder engagement
• Partnering and establishing financing for future development
• Establishing a foundation for price that is balanced and sustainable
• Achieving an efficient and timely access to market with equal access for patients
around the world
• Achieving timely and correct diagnosis to enable higher quality of life and more time
and information for developers
More information: http://www.orphandrugssummit.com/
Healthcare providers are increasingly breaking the secure supply chain and endangering patients. Learn about counterfeit drugs and most recent incidents involving providers.
Also learn about how you can be a part of the solution by working with the Partnership for Safe Medicines.
Eighty percent of Americans believe the prices of prescription medications are unreasonable. PharmacyChecker president and co-founder, Gabriel Levitt, spoke at the New York Retirees Association of District Council 37 September 2018 meeting about the prescription drug price crisis in America and how international online pharmacies can help seniors today. With around 200-300 members in attendance, the members didn’t hold back in expressing shock at the numbers surrounding the current state of drug prices in the United States vs. the rest of the world. Commonly prescribed drugs, that many uninsured or under-insured Americans can’t afford are much less in Canada and other countries.
In this SlideShare, we'll provide an overview of the biggest vaccination campaign in history. Since governments around the world began vaccinating their populations in December 2020, there is a striking gap between higher-income countries with the rest of the world. To date (10th June 2021), more than 2.25 billion doses have been administered, yet low-income countries are still far behind, receiving only 0.3% of doses administered.
Changing times ask for solid relationships.
Times are changing. A renewed interest from big pharma in the rare disease landscape
has awakened due to large-scale patent expirations, competition from generics &
biosimilars, anemic pipelines, escalating clinical trial costs and a global health-care
reform. This means that the traditional blockbuster model has become less viable while
the revenue-generating potential of orphan drugs has shown to be huge with a greater
return on investment than non-orphan drugs. According to EvaluatePharma, the orphan
drugs sales will grow at an annual rate of 11% and constitute 19% of the total share of
prescription drugs by 2020, totalling 176 billion dollars.
The rare disease landscape is very complex due to the large amount of stakeholders
involved. Despite their different interests they have one goal in common: getting an
orphan drug approval that will help save or improve lives. But there are many challenges
on the road to orphan drug designation:
• Complex and changing national and regional regulations
• Clinical trial design and finding & keeping patients
• The lack of a central database designed specifically to list patient registries, which
asks for close stakeholder engagement
• Partnering and establishing financing for future development
• Establishing a foundation for price that is balanced and sustainable
• Achieving an efficient and timely access to market with equal access for patients
around the world
• Achieving timely and correct diagnosis to enable higher quality of life and more time
and information for developers
More information: http://www.orphandrugssummit.com/
Healthcare providers are increasingly breaking the secure supply chain and endangering patients. Learn about counterfeit drugs and most recent incidents involving providers.
Also learn about how you can be a part of the solution by working with the Partnership for Safe Medicines.
Please read below case and individually take the role of “NGOsAdvoc.pdfpallavi953613
Please read below case and individually take the role of “NGOs/Advocacy Groups” as one of the
important stakeholder.
Discuss the case, from your chosen stakeholder as “NGOs/Advocacy Groups” and perspective
analyzing the reasons for the current situation and the changes you would propose for the future,
supported with additionally researched relevant information.
Please mention your list of references and at least 400 words.
In-Depth Integrative Case 1.2
Pharmaceutical Companies, Intellectual Property,
and the Global AIDS Epidemic
In August 2003, after heavy lobbying from nongovernmental
organizations (NGOs) such as Doctors Without
Borders, the U.S. pharmaceutical industry finally dropped
its opposition to relaxation of the intellectual property
rights (IPR) provisions under World Trade Organization
(WTO) regulations to make generic, low-cost antiviral
drugs available to developing countries like South Africa
facing epidemics or other health emergencies. 1 Although
this announcement appeared to end a three-year dispute
between multinational pharmaceutical companies, governments,
and NGOs over the most appropriate and effective
response to viral pandemics in the developing world, the
specific procedures for determining what constitutes a
health emergency had yet to be worked out. Nonetheless,
the day after the agreement was announced, the government
of Brazil said it would publish a decree authorizing
imports of generic versions of patented AIDS drugs that
the country said it could no longer afford to buy from
multinational pharmaceutical companies. Although the
tentative WTO agreement would appear to allow such
production under limited circumstances, former U.S. trade
official Jon Huenemann remarked, “They’re playing with
fire. . . . The sensitivities of this are obvious and we’re
right on the edge here.”
Despite the role of developed and developing country
governments, NGOs, large pharmaceutical companies,
and their generic competitors in crafting this agreement,
it was unclear how it would be implemented and whether
action would be swift enough to stem the HIV/AIDS epidemic
ravaging South Africa and many other countries.
The AIDS Epidemic and Potential
Treatment
In 2008, after over two decades of fighting the AIDS epidemic
and raising the public awareness, HIV/AIDS still
remained one of the leading causes of death in the world,
occupying the 6th position in WHO Top 10 Causes of
Death list. 3 According to the World Health Organization
(WHO), in 2008 there were approximately 33.4 million
people living with AIDS, with 2.7 million newly infected,
and 2 millions deaths (see Table 1). Since 1980, AIDS has
killed more than 25 million people. HIV is especially
deadly because it often remains dormant in an infected person
for years without showing symptoms and is transmitted
to others often without the knowledge of either person. HIV
leads to AIDS when the virus attacks the immune system
and cripples it, making the person vulnerable to diseases. 4
Th.
Insights on the major changes occuring in healthcare. One article on health and wellbeing in a major pharma, by thier Director HSE, illustrates the challenge of getting meaningful metrics published, and the weak link with company financials.
The Opioid Crisis: The Important Role of CPAsPYA, P.C.
PYA Senior Manager Valerie Rock presented “The Opioid Crisis: The Important Role of CPAs,” which provided:
-An overview of the crisis.
-An outline of risk areas that require internal controls.
-Examples of monitoring for opioid crisis fraud and abuse cases.
Indian pharmaceutical industry: Policies, achievements and challengesRajesh Kochhar
Indian pharmaceutical industry is a success story from a national as well as third-world perspective. India accounts for 10% of world production and ranks third in the world in terms of volume. In value terms the share is only 1.4% and the rank 14th.
his statistic underlines the important fact that India produces world-class generic drugs at a very low cost. Indian domestic pharma market, currently evaluated at $12 bn, is largely self-sufficient with patented drugs playing a minimal role.
Rem de sivir - a classic analysis of desperate measures during desperate timesDr Siddharth Dutta
Perception driven pharma sales of a drug, which lacked data from clinical trials and patients. Billions of dollars spent on something which WHO claims have limited or no effect. Can we afford such luxury in 2020?
Please read below case and individually take the role of “NGOsAdvoc.pdfpallavi953613
Please read below case and individually take the role of “NGOs/Advocacy Groups” as one of the
important stakeholder.
Discuss the case, from your chosen stakeholder as “NGOs/Advocacy Groups” and perspective
analyzing the reasons for the current situation and the changes you would propose for the future,
supported with additionally researched relevant information.
Please mention your list of references and at least 400 words.
In-Depth Integrative Case 1.2
Pharmaceutical Companies, Intellectual Property,
and the Global AIDS Epidemic
In August 2003, after heavy lobbying from nongovernmental
organizations (NGOs) such as Doctors Without
Borders, the U.S. pharmaceutical industry finally dropped
its opposition to relaxation of the intellectual property
rights (IPR) provisions under World Trade Organization
(WTO) regulations to make generic, low-cost antiviral
drugs available to developing countries like South Africa
facing epidemics or other health emergencies. 1 Although
this announcement appeared to end a three-year dispute
between multinational pharmaceutical companies, governments,
and NGOs over the most appropriate and effective
response to viral pandemics in the developing world, the
specific procedures for determining what constitutes a
health emergency had yet to be worked out. Nonetheless,
the day after the agreement was announced, the government
of Brazil said it would publish a decree authorizing
imports of generic versions of patented AIDS drugs that
the country said it could no longer afford to buy from
multinational pharmaceutical companies. Although the
tentative WTO agreement would appear to allow such
production under limited circumstances, former U.S. trade
official Jon Huenemann remarked, “They’re playing with
fire. . . . The sensitivities of this are obvious and we’re
right on the edge here.”
Despite the role of developed and developing country
governments, NGOs, large pharmaceutical companies,
and their generic competitors in crafting this agreement,
it was unclear how it would be implemented and whether
action would be swift enough to stem the HIV/AIDS epidemic
ravaging South Africa and many other countries.
The AIDS Epidemic and Potential
Treatment
In 2008, after over two decades of fighting the AIDS epidemic
and raising the public awareness, HIV/AIDS still
remained one of the leading causes of death in the world,
occupying the 6th position in WHO Top 10 Causes of
Death list. 3 According to the World Health Organization
(WHO), in 2008 there were approximately 33.4 million
people living with AIDS, with 2.7 million newly infected,
and 2 millions deaths (see Table 1). Since 1980, AIDS has
killed more than 25 million people. HIV is especially
deadly because it often remains dormant in an infected person
for years without showing symptoms and is transmitted
to others often without the knowledge of either person. HIV
leads to AIDS when the virus attacks the immune system
and cripples it, making the person vulnerable to diseases. 4
Th.
Insights on the major changes occuring in healthcare. One article on health and wellbeing in a major pharma, by thier Director HSE, illustrates the challenge of getting meaningful metrics published, and the weak link with company financials.
The Opioid Crisis: The Important Role of CPAsPYA, P.C.
PYA Senior Manager Valerie Rock presented “The Opioid Crisis: The Important Role of CPAs,” which provided:
-An overview of the crisis.
-An outline of risk areas that require internal controls.
-Examples of monitoring for opioid crisis fraud and abuse cases.
Indian pharmaceutical industry: Policies, achievements and challengesRajesh Kochhar
Indian pharmaceutical industry is a success story from a national as well as third-world perspective. India accounts for 10% of world production and ranks third in the world in terms of volume. In value terms the share is only 1.4% and the rank 14th.
his statistic underlines the important fact that India produces world-class generic drugs at a very low cost. Indian domestic pharma market, currently evaluated at $12 bn, is largely self-sufficient with patented drugs playing a minimal role.
Rem de sivir - a classic analysis of desperate measures during desperate timesDr Siddharth Dutta
Perception driven pharma sales of a drug, which lacked data from clinical trials and patients. Billions of dollars spent on something which WHO claims have limited or no effect. Can we afford such luxury in 2020?
What are the main advantages of using HR recruiter services.pdfHumanResourceDimensi1
HR recruiter services offer top talents to companies according to their specific needs. They handle all recruitment tasks from job posting to onboarding and help companies concentrate on their business growth. With their expertise and years of experience, they streamline the hiring process and save time and resources for the company.
Implicitly or explicitly all competing businesses employ a strategy to select a mix
of marketing resources. Formulating such competitive strategies fundamentally
involves recognizing relationships between elements of the marketing mix (e.g.,
price and product quality), as well as assessing competitive and market conditions
(i.e., industry structure in the language of economics).
RMD24 | Debunking the non-endemic revenue myth Marvin Vacquier Droop | First ...BBPMedia1
Marvin neemt je in deze presentatie mee in de voordelen van non-endemic advertising op retail media netwerken. Hij brengt ook de uitdagingen in beeld die de markt op dit moment heeft op het gebied van retail media voor niet-leveranciers.
Retail media wordt gezien als het nieuwe advertising-medium en ook mediabureaus richten massaal retail media-afdelingen op. Merken die niet in de betreffende winkel liggen staan ook nog niet in de rij om op de retail media netwerken te adverteren. Marvin belicht de uitdagingen die er zijn om echt aansluiting te vinden op die markt van non-endemic advertising.
Affordable Stationery Printing Services in Jaipur | Navpack n PrintNavpack & Print
Looking for professional printing services in Jaipur? Navpack n Print offers high-quality and affordable stationery printing for all your business needs. Stand out with custom stationery designs and fast turnaround times. Contact us today for a quote!
VAT Registration Outlined In UAE: Benefits and Requirementsuae taxgpt
Vat Registration is a legal obligation for businesses meeting the threshold requirement, helping companies avoid fines and ramifications. Contact now!
https://viralsocialtrends.com/vat-registration-outlined-in-uae/
Premium MEAN Stack Development Solutions for Modern BusinessesSynapseIndia
Stay ahead of the curve with our premium MEAN Stack Development Solutions. Our expert developers utilize MongoDB, Express.js, AngularJS, and Node.js to create modern and responsive web applications. Trust us for cutting-edge solutions that drive your business growth and success.
Know more: https://www.synapseindia.com/technology/mean-stack-development-company.html
Putting the SPARK into Virtual Training.pptxCynthia Clay
This 60-minute webinar, sponsored by Adobe, was delivered for the Training Mag Network. It explored the five elements of SPARK: Storytelling, Purpose, Action, Relationships, and Kudos. Knowing how to tell a well-structured story is key to building long-term memory. Stating a clear purpose that doesn't take away from the discovery learning process is critical. Ensuring that people move from theory to practical application is imperative. Creating strong social learning is the key to commitment and engagement. Validating and affirming participants' comments is the way to create a positive learning environment.
Enterprise Excellence is Inclusive Excellence.pdfKaiNexus
Enterprise excellence and inclusive excellence are closely linked, and real-world challenges have shown that both are essential to the success of any organization. To achieve enterprise excellence, organizations must focus on improving their operations and processes while creating an inclusive environment that engages everyone. In this interactive session, the facilitator will highlight commonly established business practices and how they limit our ability to engage everyone every day. More importantly, though, participants will likely gain increased awareness of what we can do differently to maximize enterprise excellence through deliberate inclusion.
What is Enterprise Excellence?
Enterprise Excellence is a holistic approach that's aimed at achieving world-class performance across all aspects of the organization.
What might I learn?
A way to engage all in creating Inclusive Excellence. Lessons from the US military and their parallels to the story of Harry Potter. How belt systems and CI teams can destroy inclusive practices. How leadership language invites people to the party. There are three things leaders can do to engage everyone every day: maximizing psychological safety to create environments where folks learn, contribute, and challenge the status quo.
Who might benefit? Anyone and everyone leading folks from the shop floor to top floor.
Dr. William Harvey is a seasoned Operations Leader with extensive experience in chemical processing, manufacturing, and operations management. At Michelman, he currently oversees multiple sites, leading teams in strategic planning and coaching/practicing continuous improvement. William is set to start his eighth year of teaching at the University of Cincinnati where he teaches marketing, finance, and management. William holds various certifications in change management, quality, leadership, operational excellence, team building, and DiSC, among others.
Discover the innovative and creative projects that highlight my journey throu...dylandmeas
Discover the innovative and creative projects that highlight my journey through Full Sail University. Below, you’ll find a collection of my work showcasing my skills and expertise in digital marketing, event planning, and media production.
Discover the innovative and creative projects that highlight my journey throu...
Evangeline Chee - China and India making inroads in Biotech Drugs
1. China and India Making Inroads in Biotech Drugs<br />By GARDINER HARRIS<br />Chinese and Indian drug makers have taken over much of the global trade in medicines and now manufacture more than 80 percent of the active ingredients in drugs sold worldwide. But they had never been able to copy the complex and expensive biotech medicines increasingly used to treat cancer, diabetes and other diseases in rich nations like the United States — until now. <br />These generic drug companies say they are on the verge of selling cheaper copies of such huge sellers as Herceptin for breast cancer, Avastin for colon cancer, Rituxan for non-Hodgkin’s lymphoma and Enbrel for rheumatoid arthritis. Their entry into the market in the next year — made possible by hundreds of millions of dollars invested in biotechnology plants — could not only transform the care of patients in much of the world but also ignite a counterattack by major pharmaceutical companies and diplomats from richer countries. <br />Already, the Obama administration has been trying to stop an effort by poorer nations to strike a new international bargain that would allow them to get around patent rights and import cheaper Indian and Chinese knock-off drugs for cancer and other diseases, as they did to fight AIDS. The debate turns on whether diseases like cancer can be characterized as emergencies, or “epidemics.” <br />Rich nations and the pharmaceutical industry agreed 10 years ago to give up patent rights and the profits that come with them in the face of an AIDS pandemic that threatened to depopulate much of Africa, but they see deaths from cancer, diabetes and other noncommunicable diseases as less of an emergency and, in some cases, the inevitable consequence of better and longer living. <br />The debate has intensified in recent weeks, before world leaders gather at the United Nations on Monday and Tuesday to confront surging deaths from noncommunicable diseases, which cause two-thirds of all deaths. It is only the second global health issue that the United Nations General Assembly has deemed urgent enough to call a meeting to discuss. <br />Participants in the negotiations, which include nongovernmental organizations, described the Obama administration’s position on the issue and provided e-mails from European diplomats that laid out the American stance, which has been adopted in the agreement’s working draft. <br />Although the draft agreement for this week’s meeting at the United Nations offers no support for poor nations seeking freer patent rules to fight cancer and other noncommunicable diseases, their advocates have vowed to continue fighting to loosen those restrictions not only this week in New York but in continuing international trade negotiations around the world as well. <br />United States officials repeatedly declined to explain the American position, though Mark Toner, a State Department spokesman, said Friday, “Regardless of what you call it, this is clearly such a pressing challenge globally that world leaders are gathering in New York next week to discuss ways to confront this threat.” <br />The United States government has a long history of pushing for strong patent protections in international trade and other agreements to protect important domestic industries like pharmaceuticals and ensure continued incentives for further inventions. <br />The new biotech copycats are likely to stir sharp debate among advocates for the poor. Already, some contend that the billions spent to treat AIDS have crowded out cheap and simple solutions to other afflictions of poverty, like childhood diarrhea. <br />The copycats will be less expensive than the originals, but they will never be cheap. It is unlikely that many African nations will be able to afford such a costly medicine for breast cancer, when far cheaper ones for colon and testicular cancer are going wanting. <br />Dr. Yusuf K. Hamied, chairman of the Indian drug giant Cipla Ltd., electrified the global health community a decade ago when he said he could produce cocktails of AIDS medicines for $1 per day — a fraction of the price charged by branded pharmaceutical companies. That price has since fallen to 20 cents per day, and more than six million people in the developing world now receive treatment, up from little more than 2,000 in 2001. <br />Dr. Hamied said in a telephone interview last week that he and a Chinese partner, BioMab, had together invested $165 million to build plants in India and China to produce at least a dozen biotech medicines. Other Indian companies have also built such plants. Since these medicines are made with genetically engineered bacteria, they must be tested extensively in patients before sale. <br />Once those tests are complete, Dr. Hamied promised to sell the drugs at a third of their usual prices, which typically cost tens of thousands of dollars for a course of treatment. <br />“And once we recover our costs, our prices will fall further,” he said. “A lot further.” <br />Dr. Peter Piot, a former director of U.N.AIDS, the United Nations AIDS agency, said the parallels between the current dilemma over cancer drugs and the one 10 years ago over AIDS medicines were striking. “Without a major reduction in the prices of the essential oncology drugs, there’s no way we can really improve survival from cancer,” said Dr. Piot, currently the director of the London School of Hygiene and Tropical Medicine. <br />But he also said he was more cautious about the promise of generics this time, because biotech medicines were not easy to copy. “I believe these medicines will make a huge difference, but I would like to see the evidence that the quality is good before giving it to my patients or taking it myself,” he said. <br />Having suffered global opprobrium 10 years ago when they were seen as blocking efforts to save the lives of millions of poor AIDS patients, executives for branded drug makers are far more cautious this time about insisting that high prices are necessary. Sara Radcliffe, a spokeswoman for the Biotechnology Industry Organization, said companies supported copycat versions of biotech medicines as long as “countries do not abuse the flexibilities in international law with respect to compulsory licensing in true public health emergencies.” <br />Patents generally provide inventors rights to 20 years of exclusive sales, but international law allows countries to force companies to share those rights with competitors under a variety of circumstances, including to protect public health. Even then, countries are generally not allowed to export the products that result from forced patent sharing except under dire circumstances. <br />But the only way poor countries can get drugs that result from shared patent rights is if another country exports those medicines to them under emergency exceptions. <br />In retrospect, the battle 10 years ago over AIDS medicines was a small skirmish compared with the one likely to erupt over cancer, diabetes and heart medicines. The AIDS drug market was never a major moneymaker for global drug giants, while cancer and diabetes drugs are central to the companies’ very survival. Roche Holding Ltd. earns $19 billion annually, or half its annual drug sales, selling Rituxan, Avastin and Herceptin. And sales of Herceptin have been rising faster in the developing world than in richer nations — making the developing world a crucial market. For middle-income countries straining to provide the best medicine possible, the new copycat biotechs will almost certainly be warmly received. <br />Mexico alone spends about $120 million buying Herceptin to treat women with breast cancer, which is nearly one-half of 1 percent of all government spending on health care, said Dr. Alejandro Mohar, general director of the Mexican National Cancer Institute. In 2007, Mexico guaranteed access to Herceptin for all women with breast cancer through a public insurance program. <br />“We would love to have better access to better drugs,” Dr. Mohar said. “This debate is going to heat up.” <br />Hermillia Villegas, a 47-year-old mother of two in Jalisco, Mexico, recently learned that she had a virulent form of breast cancer that responded well to treatment with Herceptin. Her husband is a janitor, and her doctor initially told her that each of 17 treatments with Herceptin would cost her more than $3,000. <br />“I don’t have that kind of money,” she said in a telephone interview. The new health insurance program, which pays for the whole cost of the drug, has saved her life, she said.<br />